

4P-Pharma announces the entry into its capital of M comme Mutuelle

4P-Pharma, a biotechnology company specializing in the development of new medicines in the areas of cancer, inflammatory diseases, and stimulants abuse, announces the entry into its capital of M comme Mutuelle. This new funding will help support the first phase I clinical trial led by 4P-Pharma.

4P-Pharma, founded in 2014, aims to develop early preclinical-stage innovative molecules and bring them to the first phases of clinical trials. The company positions itself as an intermediary between holders of biomedical projects with high potential, and pharmaceutical companies. 4P-Pharma business model is based on a co-develop, co-share and co-risk model with the objective to move, as quickly as possible, these new drugs to the clinic.

4P-Pharma, incubated by Eurasanté, is the first biotechnology company in which M comme Mutuelle chose to invest. This decision marks the will of M comme Mutuelle to participate fully in the economic development of the Health and Biotechnology sectors in the Hauts de France, notably by providing support to Eurasanté and its bio-incubator activities of innovative biotech companies, such as 4P-Pharma.

M comme Mutuelle will act as a long-term partner of 4P-Pharma, to financially support the phase I clinical trial of 4P-003, a molecule with stimulant abuse deterrent properties. Moreover, the health insurance company may also support other projects or clinical trials, on an ad hoc basis.

"We are delighted about this new partnership with M comme Mutuelle. This represents a new stage in the financial development of 4P-Pharma. This is indeed our first shareholder, marking the opening of our capital to outside investors. This partnership with M comme Mutuelle, will help support our first clinical trial. The collaboration between our companies makes sense; M comme Mutuelle is at the service of its customers health, and we aim to develop innovative medicines to answer unmet medical needs" says Revital Rattenbach, CEO, 4P- Pharma.

../..

The co-development projects concluded with its partners, the financial support of the Banque Publique d'Investissement, and the region Hauts de France, along with this new financial funding allowed 4P- Pharma to obtain 1.2 million euros since the beginning of its activity.

"Through this partnership with 4P-Pharma, M comme Mutuelle continues to support the economic development of the region, and particularly its savoir-faire in the Health sector. Our support can translate, as with 4P-Pharma, into entering the company's capital, but also in other instances in distributing a company's offer, or even in co-creating structures. These activities are in line with our ambition to ensure the well-being of our customers and all of our stakeholders" says Jérôme Rehlinger, CEO of M comme Mutuelle.

About M comme Mutuelle

With 150 years of health insurance experience at the service of the Health and welfare of its customers, M comme Mutuelle is among France top 30 health insurance companies. Based historically in the Hauts-de-France and Normandy regions, M comme Mutuelle serves 253,000 people throughout France, via individual or group health contracts, but also through Protection, Prevention, Insurance and Savings plans.

6000 companies have already entrusted the health of their employees to M comme Mutuelle, and 90,000 independent workers lean on M comme Mutuelle to manage their R.S.I. (Health Plan of Independents). M comme Mutuelle and its 350 employees rely on a network of 23 branches spread over six French departments.

Committed to be a local actor and service provider, M comme Mutuelle is seeking to be an active player in the health sector, but also in the preventive healthcare sector and is committed to the community by supporting various local or national initiatives. This can translate into business creation sponsorship, encouragement for entrepreneurship or support for health research in general.

www.mcommemutuelle.com
@McommeMutuelle

About 4P-Pharma

4P-Pharma is a company focusing on preclinical research and specializing in the development of new, innovative and first-in-class medical drugs and therapeutic agents, that meet unfulfilled medical needs in the fields of oncology and inflammatory diseases and notably for therapeutic indications of rare diseases.

The activity of 4P-Pharma is based on acquiring licensing options for innovative technologies at an early stage of development in the biomedical field, following the detection and the assessment of innovative projects derived from academic laboratories and Universities, from French SATTs (Technology Transfer Acceleration Companies), from technology transfer offices as well as from start-ups and firms in the pharmaceutical and biotechnology sector.

4P-Pharma defines and implements a co-development maturation project with the partner that is the owner of the rights, so as to speed up technology development time and reduce the risks connected with the initial validation phases. If the outcome of the maturation program is positive, 4P Pharma exercises a licensing option for the developed technologies and implements regulatory preclinical development until phase I/IIa is reached.

www.4p-pharma.com
www.linkedin.com/company/4p-pharma
@4P_Pharma

■ **Press contact M comme Mutuelle**

■ **Ghislain Fauquet**, communications director
■ Phone : 33 (0)6 48 77 12 04 – E-Mail : gfauquet@mcommemutuelle.com

■ **Press contact 4P-Pharma**

■ **Keren Bismuth**, scientific communications manager
■ Phone : 33 (0)9 72 84 72 64. E-Mail : keren@4p-pharma.com